DxTech Enters Into Long-Term Strategic Alliance With Nicholas Piramal for
Point-of-Care Diagnostic Testing System
MERRIMACK, New Hampshire, April 30 /PRNewswire/ -- DxTech LLC ("DxTech"), an innovation company focused on putting high-quality diagnostic information in the hands of physicians in real time, has entered into a long-term strategic alliance with Nicholas Piramal India Limited ("NPIL"), one of the largest pharmaceutical and healthcare companies in India. The alliance includes a License and Development Agreement relating to DxTech's proprietary technology, a Distribution Agreement and an agreement to establish a joint venture between the companies for the marketing and sales of the commercial product.
DxTech is developing the fully-integrated, Vantix(TM) point-of-care ("POC") diagnostics platform based on proprietary, electrochemical sensor technology that has unparalleled sensitivity and dynamic range. This combination will allow DxTech to bring two points of differentiation to the POC market that cannot be realized by any other POC technology currently available: the capability to conduct simultaneous diagnostic immunoassays and general chemistries on a single cartridge delivering a uniquely broad range of tests.
In addition to its core focus on the US$48 billion routine diagnostic market in the US, DxTech's Vantix(TM) platform also has the added potential to transform diagnostic testing in a range of other emerging markets, including Asia, parts of Europe, and Central and Latin America. In these markets, the Vantix(TM) platform could reduce or eliminate the need for expensive, centralised laboratory infrastructures and replace them with equally accurate testing that has a more favourable cost profile, distributed across each POC.
The Vantix(TM) platform is designed to meet or exceed the performance
levels established by US reference laboratories, to provide a complete
solution from sample collection thr
|SOURCE DxTech and Nicholas Piramal|
Copyright©2008 PR Newswire.
All rights reserved